__NUXT_JSONP__("/drugs/Azacitidine", (function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with \u003E 30% marrow blasts according to the WHO classification.",inn:b,marketingAuthorisationDate:"2020-03-27 01:00:00",marketingAuthorisationHolder:"Mylan Ireland Limited",medicineName:"Azacitidine Mylan",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fazacitidine-mylan"},{activeSubstance:b,conditionIndication:"Onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT).",inn:b,marketingAuthorisationDate:"2021-06-17 00:00:00",marketingAuthorisationHolder:h,medicineName:i,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fonureg"},{activeSubstance:b,conditionIndication:"Azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 % to 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 % to 30 % blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification,AML with \u003E 30 % marrow blasts according to the WHO classification.",inn:b,marketingAuthorisationDate:"2020-03-24 01:00:00",marketingAuthorisationHolder:"betapharm Arzneimittel GmbH",medicineName:"Azacitidine betapharm",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fazacitidine-betapharm"},{activeSubstance:b,conditionIndication:"Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),- chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,- acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,- AML with \u003E30% marrow blasts according to the WHO classification.",inn:b,marketingAuthorisationDate:"2020-02-13 01:00:00",marketingAuthorisationHolder:"Accord Healthcare S.L.U.",medicineName:"Azacitidine Accord",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fazacitidine-accord"},{activeSubstance:b,conditionIndication:"Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with \u003E30% marrow blasts according to the WHO classification.",inn:b,marketingAuthorisationDate:"2008-12-17 01:00:00",marketingAuthorisationHolder:h,medicineName:j,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fvidaza"}],fdaDrugLabel:[{brand:"ONUREG",indication:"1 INDICATIONS AND USAGE ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ).",manufacturer:k,splSetId:"0e95e33f-8aba-4f19-b332-2416580d358b"},{brand:a,indication:c,manufacturer:"Mylan Institutional LLC",splSetId:"113af8ed-ac29-41a9-bbbb-5d03d654846b"},{brand:a,indication:d,manufacturer:f,splSetId:"33397835-15a9-d89f-bd75-8b915f5c4dbf"},{brand:"VIDAZA",indication:"1 INDICATIONS AND USAGE VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1 ) 1.1 Myelodysplastic Syndromes (MDS) VIDAZA ® is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).",manufacturer:k,splSetId:"3495a71a-cc04-4776-851f-f185956f32af"},{brand:a,indication:c,manufacturer:"Fresenius Kabi USA, LLC",splSetId:"3b594aba-e798-4105-b801-0b0d970747c1"},{brand:a,indication:l,manufacturer:m,splSetId:"3b96b508-046b-49ae-aefe-6d39c89a1d0e"},{brand:a,indication:c,manufacturer:n,splSetId:"5235e12f-7198-47e1-a7e3-d3982b367e95"},{brand:"azacitidine for",indication:d,manufacturer:o,splSetId:"52b19d87-b646-4a00-bdd4-ac826860b719"},{brand:a,indication:c,manufacturer:p,splSetId:"55915b5d-0e85-4ede-ad4f-ac89670d8973"},{brand:e,indication:g,manufacturer:"Armas Pharmaceuticals Inc.",splSetId:"5c0a2d5f-8c34-4c04-8425-7543965cedd4"},{brand:a,indication:"1 INDICATIONS AND USAGE Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL) ( 1 ). 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for Injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML).",manufacturer:n,splSetId:"5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a"},{brand:a,indication:c,manufacturer:"Breckenridge Pharmaceutical, Inc.",splSetId:"5facf2e9-f0d9-4be5-bcfa-5b85dd519c11"},{brand:a,indication:c,manufacturer:"Accord Healthcare Inc.",splSetId:"70140e11-33f1-2240-e053-2991aa0a0480"},{brand:a,indication:d,manufacturer:f,splSetId:"71d8d758-86c9-b571-aed1-719654fd4b82"},{brand:a,indication:d,manufacturer:"NorthStar RxLLC",splSetId:"81366ec1-9689-4857-ded6-3d6342fe5132"},{brand:a,indication:c,manufacturer:p,splSetId:"87f7a39d-06db-48ca-be21-9e8806608439"},{brand:a,indication:l,manufacturer:m,splSetId:"97b0917a-03fa-4cc4-91cf-1bed57a988c9"},{brand:a,indication:c,manufacturer:"Panacea Biotec Limited",splSetId:"9abb489d-ce54-4140-83f6-b756f00b0967"},{brand:a,indication:"1 INDICATIONS AND USAGE Azacitidine is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1 ) 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).",manufacturer:o,splSetId:"ad4ac593-b811-4d5a-a336-edb98689f188"},{brand:e,indication:c,manufacturer:"Wockhardt USA LLC.",splSetId:"adc095f0-46ca-431e-8264-8cc740a1d3b3"},{brand:e,indication:g,manufacturer:"CELLTRION USA, INC.",splSetId:"b4bcca95-d0b0-42dd-9dbb-637ab98effcc"},{brand:"AZACITIDINE AZACITIDINE",indication:g,manufacturer:f,splSetId:"d38a1247-28c8-a911-e691-a983a2f9a6e3"},{brand:a,indication:"1 INDICATIONS AND USAGE Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for Injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).",manufacturer:"Hikma Pharmaceuticals USA Inc.",splSetId:"ff73515d-bd55-4eb5-992b-d2138c80887e"}],id:a,nciThesaurus:{casRegistry:"320-67-2",chebiId:"CHEBI:2038",chemicalFormula:"C8H12N4O5",definition:"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity.",fdaUniiCode:"M801H13NRU",identifier:"C288",preferredName:a,semanticType:"Nucleic Acid, Nucleoside, or Nucleotide",subclassOf:[],synonyms:["4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one","5 AZC","5-AC","5-AZC","5-Aza-cytidine","5-Azacytidine",e,a,"Azacytidine","Azacytidine, 5-","Ladakamycin","Mylosar",i,"U-18496",j,b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAzacitidine",extension:".json",createdAt:"2021-10-30T13:38:38.623Z",updatedAt:"2021-10-30T13:38:38.633Z"}}],fetch:{},mutations:void 0}}("Azacitidine","azacitidine","1 INDICATIONS AND USAGE Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1 ) 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).","1 INDICATIONS AND USAGE Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).","AZACITIDINE","Dr. Reddy's Laboratories Inc.","1 INDICATIONS AND USAGE Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1) 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).","Bristol-Myers Squibb Pharma EEIG","Onureg","Vidaza","Celgene Corporation","1 INDICATIONS AND USAGE Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1 ) 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for Injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).","Meitheal Pharmaceuticals Inc.","BluePoint Laboratories","Cipla USA Inc.","Sandoz Inc")));